These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10631755)

  • 41. Evaluation of antitubercular drug insertion into preformed dipalmitoylphosphatidylcholine monolayers.
    Chimote G; Banerjee R
    Colloids Surf B Biointerfaces; 2008 Apr; 62(2):258-64. PubMed ID: 18082382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Localized rifampicin albumin microspheres.
    Pande S; Vyas SP; Dixit VK
    J Microencapsul; 1991; 8(1):87-93. PubMed ID: 1880695
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of environmental stresses on stability of oil-in-water emulsions containing droplets stabilized by beta-lactoglobulin-iota-carrageenan membranes.
    Gu YS; Regnier L; McClements DJ
    J Colloid Interface Sci; 2005 Jun; 286(2):551-8. PubMed ID: 15897070
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Principles of emulsion stabilization with special reference to polymeric surfactants.
    Tadros T
    J Cosmet Sci; 2006; 57(2):153-69. PubMed ID: 16688378
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of hydrophilic surfactants on the properties of multiple W/O/W emulsions.
    Schmidts T; Dobler D; Nissing C; Runkel F
    J Colloid Interface Sci; 2009 Oct; 338(1):184-92. PubMed ID: 19595359
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lectin-functionalized multiple emulsions for improved cancer therapy.
    Khopade AJ; Nandakumar KS; Jain NK
    J Drug Target; 1998; 6(4):285-92. PubMed ID: 9894696
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
    Danckwerts MP; Ebrahim S; Pillay V
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
    Pandey R; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro evaluation of food effect on the bioavailability of rifampicin from antituberculosis fixed dose combination formulations.
    Panchagnula R; Rungta S; Sancheti P; Agrawal S; Kaul CL
    Farmaco; 2003 Nov; 58(11):1099-103. PubMed ID: 14572860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Critical physicochemical and biological attributes of nanoemulsions for pulmonary delivery of rifampicin by nebulization technique in tuberculosis treatment.
    Shah K; Chan LW; Wong TW
    Drug Deliv; 2017 Nov; 24(1):1631-1647. PubMed ID: 29063794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery.
    Sung JC; Padilla DJ; Garcia-Contreras L; Verberkmoes JL; Durbin D; Peloquin CA; Elbert KJ; Hickey AJ; Edwards DA
    Pharm Res; 2009 Aug; 26(8):1847-55. PubMed ID: 19407933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Entrapment of multiple anti-Tb drugs in microemulsion system: quantitative analysis, stability, and in vitro release studies.
    Mehta SK; Kaur G; Bhasin KK
    J Pharm Sci; 2010 Apr; 99(4):1896-911. PubMed ID: 19894276
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Studies on a reverse micelle-lamellar phase transition based depot preparation of rifampicin.
    Uppadhyay AK; Omray LK; Khopade AJ; Jain NK
    Pharmazie; 1997 Dec; 52(12):961-2. PubMed ID: 9442561
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients.
    Verbeeck RK; Singu BS; Kibuule D
    Clin Pharmacokinet; 2019 Dec; 58(12):1511-1515. PubMed ID: 31332668
    [No Abstract]   [Full Text] [Related]  

  • 56. PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug.
    Kumar PV; Agashe H; Dutta T; Jain NK
    Curr Drug Deliv; 2007 Jan; 4(1):11-9. PubMed ID: 17269913
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rifampicin: a new orally active rifamycin.
    Maggi N; Pasqualucci CR; Ballotta R; Sensi P
    Chemotherapy; 1966; 11(5):285-92. PubMed ID: 5958716
    [No Abstract]   [Full Text] [Related]  

  • 58. [Study on the quality and stability of mass-produced and prepared for storage ointments. V. Quality of mass-produced suspension-ointments and emulsion-suspension ointments].
    Sarsúnová M; Gremenová B; Schusterová S
    Cesk Farm; 1974 May; 23(4):139-43. PubMed ID: 4830773
    [No Abstract]   [Full Text] [Related]  

  • 59. Concanavalin-A conjugated fine-multiple emulsion loaded with 6-mercaptopurine.
    Khopade AJ; Jain NK
    Drug Deliv; 2000; 7(2):105-12. PubMed ID: 10892411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Formulation of shear rate sensitive multiple emulsions.
    Muguet V; Seiller M; Barratt G; Ozer O; Marty JP; Grossiord JL
    J Control Release; 2001 Jan; 70(1-2):37-49. PubMed ID: 11166406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.